Details for Patent: 7,462,626
✉ Email this page to a colleague
Which drugs does patent 7,462,626 protect, and when does it expire?
Patent 7,462,626 protects CONTRAVE and is included in one NDA.
This patent has thirty-eight patent family members in twenty-three countries.
Summary for Patent: 7,462,626
| Title: | Compositions for affecting weight loss |
| Abstract: | Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a melanocortin 4 receptor (MC4-R) compared to normal physiological conditions. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance .alpha.-MSH activity. |
| Inventor(s): | Weber; Eckard (San Diego, CA), Cowley; Michael Alexander (Portland, OR) |
| Assignee: | Orexigen Therapeutics, Inc. (San Diego, CA) |
| Application Number: | 11/356,839 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 7,462,626 |
|
Patent Claim Types: see list of patent claims | Use; Formulation; Dosage form; |
Drugs Protected by US Patent 7,462,626
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nalpropion | CONTRAVE | bupropion hydrochloride; naltrexone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 200063-001 | Sep 10, 2014 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 7,462,626
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2316456 | ⤷ Sign Up | CA 2017 00062 | Denmark | ⤷ Sign Up |
| European Patent Office | 2316456 | ⤷ Sign Up | 300918 | Netherlands | ⤷ Sign Up |
| European Patent Office | 2316456 | ⤷ Sign Up | 122017000109 | Germany | ⤷ Sign Up |
| European Patent Office | 2316456 | ⤷ Sign Up | LUC00054 | Luxembourg | ⤷ Sign Up |
| European Patent Office | 2316456 | ⤷ Sign Up | 2017C/064 | Belgium | ⤷ Sign Up |
| European Patent Office | 2316456 | ⤷ Sign Up | CR 2017 00062 | Denmark | ⤷ Sign Up |
| European Patent Office | 2316456 | ⤷ Sign Up | 1790064-8 | Sweden | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
